Copyright © 2026 Knight Sac Media. All rights reserved.https://www.siliconinvestor.com/subject.aspx?subjectid=7033 Please also see discussions about PCYC under QLT area. Pharmacyclics is a company with three products in clinical development and multiple compounds in preclinical development. Their products are: Gd-Tex (gadolinium texophyrin), a radiation sensitizer. This product is in Phase I trials, which are still open for enrollment. They are studying effects on brain metastases, as well as looking at MDT's (maximum tolerable dose). Lu-Tex (lutetium texaphyrin PCI-0123), a light activated drug being studied for treatment of various cutaneous tumors, including Kaposis Sarcoma, melanoma, breast CA, and others. It is in Phase I trials, the interim results of which looked very favorable for both efficacy and toxicity. In fact, it could be a very important compound when and if they demonstrate its efficacy in trials, because the drug has a fairly short half-life, which limits its toxicity. Gadolite oral suspension, an MRI contrast agent for the GI tract. This is in Phase III trials and a NDA has been filed. I believe they will compete in a difficult but very promising market. The real question will be what , if any, advantages will Lu-Tex have over products being studied by QLT and PDT. The CEO of PCYC is Rich Miller who founded IDEC pharmaceuticals and he is supposedly a very bright guy and whatever he touches seems to work (both scientifically and for the shareholders). I am not a stock promoter nor am I a principal of the company, but I have been watching PCYC for several months and just bought some shares due to the recent weakness in its stock price, and because of the potential for its products. I would love to keep and ongoing discussion about this company. Doughttps://www.siliconinvestor.com/images/Logo380x132.pnghttps://www.siliconinvestor.com/subject.aspx?subjectid=703338013210scaram(o)uche<span id="intelliTXT">Blood. 2015 Apr 2. pii: blood-2015-01-621391. [Epub ahead of print]<br><br>Selinexor is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia.<br><br>Hing ZA1, Mantel R2, Beckwith KA1, Guinn D2, Williams E2, Smith LL2, Williams K2, Johnson AJ3, Lehman AM4, Byrd JC2, Woyach JA2, Lapalombella R5.<br><br>1Medical Scientist Training Program, The Ohio State University, Columbus, OH, United States;<br>2Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, United States;<br>3Division of Medicinal Chemistry, College of Pharmacy, The Ohio State University, Columbus, OH, United States;<br>4Center for Biostatistics, The Ohio State University, Columbus, OH, United States.<br>5Division of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, United States; rosa.lapalombella@osumc.edu.<br><br>Despite the therapeutic efficacy of ibrutinib in CLL, complete responses are infrequent and acquired resistance to BTK inhibition is being observed an increasing number of patients1,2. Combination regimens that increase frequency of complete remissions, accelerate time to remission, and overcome single agent resistance are of considerable interest. We have previously shown that the XPO1 inhibitor selinexor is pro-apoptotic in CLL cells and disrupts BCR signaling via BTK depletion. Herein we show the combination of selinexor and ibrutinib elicits a synergistic cytotoxic effect in primary CLL cells. The combination increases overall survival compared to ibrutinib alone in a mouse model of CLL. Selinexor is effective in cells isolated from patients with prolonged lymphocytosis following ibrutinib therapy. Finally, selinexor is effective in ibrutinib-refractory mice and in a cell line harboring the BTK C481S mutation. This is the first report describing the combined activity of ibrutinib and selinexor in CLL, which represents a new treatment paradigm and warrants further evaluation in clinical trials of CLL patients including those with acquired ibrutinib resistance.</span>https://www.siliconinvestor.com/readmsg.aspx?msgid=300169964/7/2015 10:01:26 AMChris12<span id="intelliTXT">Story about the President of Pharmacyclics being the largest donor to Scientology. Deeply involved it would seem.</span>https://www.siliconinvestor.com/readmsg.aspx?msgid=286929561/29/2013 2:46:22 AMWaynershttps://www.siliconinvestor.com/readmsg.aspx?msgid=282765397/18/2012 10:50:27 PMmarketfriends<span id="intelliTXT">ok, so over a longish range these guys have been steady. expecting that they will take another ride upwards. <br><br><a class='ExternURL' href='http://stockcharts.com/h-sc/ui?s=pcyc' target='_blank' >stockcharts.com</a><br><br>Sam<br>www.marketfriends.com</span>https://www.siliconinvestor.com/readmsg.aspx?msgid=279359962/8/2012 1:31:07 PMmarketfriends<span id="intelliTXT">ok, this might interest some people who have been thinking about PCYC.<br><br><a class='ExternURL' href='http://www.marketfriends.com/NewsDetail/pcyc-heavy-buying-on-this-development-co-42.aspx' target='_blank' >marketfriends.com</a></span>https://www.siliconinvestor.com/readmsg.aspx?msgid=279312622/6/2012 1:14:23 PM